ICER casts doubt on cost-effectiveness of newer MM drugs

In a draft evidence Kyprolis carfilzomib, Empliciti elotuzumab and Ninlaro ixazomib, all in combination with Revlimid lenalidomide and dexamethasone, "provide an incremental or better net health benefit for both second-line and third-line

Read the full 327 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE